Teduglutide – REKUDA

Use of teduglutide in adults with short bowel syndrome-associated intestinal failure

9. Juni 2023

Nutr Clin Pract .2023 Jun 9. doi: 10.1002/ncp.11015. Online ahead of print. Loris Pironi, Johane P Allard, Francisca Joly, Parnia Geransar, Elisabeth Genestin, Ulrich-Frank PapePMID: 37294295 DOI: 10.1002/ncp.11015 Abstract Short bowel syndrome (SBS) is a rare gastrointestinal disorder associated with intestinal failure (SBS-IF) and poor health-related outcomes. Patients with SBS-IF are unable to absorb sufficient nutrients or fluids to maintain significantly metabolic […]

Use of teduglutide in adults with short bowel syndrome-associated intestinal failure Weiterlesen »

Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure-A Nested Matched Pair Real-World Study

18. April 2023

Nutrients.2023 Apr 18;15(8):1949. doi: 10.3390/nu15081949. Elisabeth Blüthner, Ulrich-Frank Pape, Frank Tacke, Sophie Greif PMID: 37111167 DOI: 10.3390/nu15081949 Abstract Background: Quality of life (QoL) data of chronic intestinal failure (cIF) patients treated with the GLP-2 analogue teduglutide are scarce. This study aims to analyze QoL changes over time in teduglutide-treated patients and compare the results to a matched non-treated cIF control

Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure-A Nested Matched Pair Real-World Study Weiterlesen »

Long-term results of teduglutide treatment for chronic intestinal failure – Insights from a national, multi-centric patient home-care service program

26. August 2022

ORIGINAL ARTICLE| VOLUME 51, P222-230, OCTOBER 2022 Sophie Greif, Sebastian Maasberg, Jan Wehkamp, Elisabeth Blüthner, Frank Tacke, Ulrich-Frank PapeDOI: https://doi.org/10.1016/j.clnesp.2022.08.027 Abstract Background & aims: Teduglutide is a Glucagon-like peptide-2 (GLP-2) agonist indicated for the treatment of patients with parenteral support (PS) dependent short bowel syndrome (SBS) with chronic intestinal failure (cIF). Its application is accompanied by a structured

Long-term results of teduglutide treatment for chronic intestinal failure – Insights from a national, multi-centric patient home-care service program Weiterlesen »

Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency

19. Februar 2020

Dig Dis Sci. 2020 Dec;65(12):3521-3537. doi: 10.1007/s10620-020-06140-6. Epub 2020 Feb 19. Johannes Reiner, Peggy Berlin, Jakob Wobar, Holger Schäffler, Karen Bannert, Manuela Bastian, Brigitte Vollmar, Robert Jaster, Georg Lamprecht, Maria WittePMID: 32072437 DOI: 10.1007/s10620-020-06140-6 Abstract Background: In short bowel syndrome, epithelial surface loss results in impaired nutrient absorption and may lead to intestinal insufficiency or intestinal failure. Nucleotide oligomerization domain 2 (Nod2) dysfunction predisposes to the development of

Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency Weiterlesen »